Publicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (23)

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

2020

  1. A randomized study comparing different doses of superparamagnetic iron oxide tracer for sentinel lymph node biopsy in breast cancer: The SUNRISE study

    European Journal of Surgical Oncology, Vol. 46, Núm. 12, pp. 2195-2201

  2. Axillary staging based on molecular analysis: Results of the B-CLOSER-II study

    Pathology Research and Practice, Vol. 216, Núm. 11

  3. Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

    Frontiers in Oncology, Vol. 10

2018

  1. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  2. Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial): A New Tool to Guide the Excision of the Clipped Node After Neoadjuvant Treatment

    Annals of Surgical Oncology, Vol. 25, Núm. 3, pp. 784-791

  3. P95HER2–T cell bispecific antibody for breast cancer treatment

    Science Translational Medicine, Vol. 10, Núm. 461

  4. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210

2017

  1. Role of total tumour load of sentinel lymph node on survival in early breast cancer patients

    Breast, Vol. 33, pp. 8-13

2016

  1. External validation of IOTA simple descriptors and simple rules for classifying adnexal masses

    Ultrasound in Obstetrics and Gynecology, Vol. 48, Núm. 3, pp. 397-402

  2. Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts

    Oncotarget, Vol. 7, Núm. 42, pp. 67956-67965

2015

  1. Effect of cellular senescence on the growth of HER2-positive breast cancers

    Journal of the National Cancer Institute, Vol. 107, Núm. 5

  2. Patterns of HER2 gene amplification and response to anti-HER2 therapies

    PLoS ONE, Vol. 10, Núm. 6

  3. The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancer

    European Journal of Surgical Oncology, Vol. 41, Núm. 1, pp. 46-51

2014

  1. Detection of sentinel lymph node in breast cancer recurrence may change adjuvant treatment decision in patients with breast cancer recurrence and previous axillary surgery

    Breast, Vol. 23, Núm. 4, pp. 460-465

  2. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy

    Journal of the National Cancer Institute, Vol. 106, Núm. 11

  3. Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients

    Breast Cancer Research and Treatment, Vol. 147, Núm. 2, pp. 371-380

2013

  1. A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers

    Oncogene, Vol. 32, Núm. 11, pp. 1452-1459

  2. Intraoperative molecular analysis of total tumor load in sentinel lymph node: A new predictor of axillary status in early breast cancer patients

    Breast Cancer Research and Treatment, Vol. 139, Núm. 1, pp. 87-93

  3. Multidisciplinary approach to breast cancer diagnosed during pregnancy: Maternal and neonatal outcomes

    Breast, Vol. 22, Núm. 4, pp. 515-519